In this webinar, we ask ‘Why have generative chemistry methods been unable to redefine modern drug discovery and compound idea generation?’ In this session we shed light on a typical shortcoming of generative methods.
Joe McDonald, Chief Data Officer at Odyssey Therapeutics, Peter Hunt, Director of Computational Chemistry at Optibrium Ltd and Ed Champness, CSO at Optibrium discuss experiences using generative methods and their ideas on how to close the gaps.
See how Optibrium’s Inspyra iteratively learns priorities for your projects, generating compound ideas tailored to your needs. Via your interactions, Inspyra guides generative chemistry and multi-parameter optimisation capabilities. It combines the explorative power of generative methods with your expert knowledge, helping you identify better compounds faster.
Other webinars you may be interested in
The complexity of collaboration in drug discovery
Everyone knows smooth collaboration can speed up successful drug discovery projects. But how can we collaborate easily in drug discovery…
